Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301

Trial Profile

Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Astrocytoma; Tuberous sclerosis
  • Focus Therapeutic Use
  • Acronyms EXIST-LT
  • Sponsors Novartis
  • Most Recent Events

    • 04 May 2017 Planned End Date changed from 1 Feb 2026 to 25 Sep 2026.
    • 04 May 2017 Planned primary completion date changed from 1 Feb 2026 to 25 Sep 2026.
    • 27 Apr 2016 Planned End Date changed from 1 Jun 2026 to 1 Feb 2026.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top